文献速递基础与转化研究临床试验与 GCP

颗粒体蛋白前体AAV基因治疗额颞叶痴呆:转化研究与1/2期试验中期结果

Progranulin AAV gene therapy for frontotemporal dementia: translational studies and phase 1/2 trial interim results.
PubMed 文献 · Nat Med · 2024-05-14

PR006是采用AAV9载体递送颗粒体蛋白基因的试验性基因治疗。开放标签1/2期试验低剂量组6例完成12个月随访,并纳入中剂量组7例初步数据;单次小脑延髓池给药总体安全耐受,所有患者脑脊液出现抗AAV9抗体,脑脊液颗粒体蛋白前体均升高,但需更长随访确认安全性和潜在疗效。

要点

  • 低剂量组6例达12个月随访时点,中剂量组7例提供初步数据。
  • 单次小脑延髓池给予PR006总体安全且耐受良好。
  • 所有患者脑脊液出现治疗 emergent 抗AAV9抗体,无人出现抗颗粒体蛋白前体抗体。

核心结论

  • 这些数据为PR006的安全性和生物活性提供初步见解。
  • 需要更长随访和额外研究来确认PR006的安全性和潜在疗效。

研究设计与样本

  • 非临床研究评估PR006在患者诱导多能干细胞来源神经元、Grn敲除小鼠和非人灵长类中的表现。
  • 开展首次人体1/2期开放标签试验,报告预设中期分析结果,触发点为低剂量组(n=6)最后一名接受治疗患者达到12个月随访时点。
  • 同时纳入中剂量组(n=7)的初步数据。
  • 主要终点为安全性、免疫原性和脑脊液及血液中颗粒体蛋白前体水平变化。
  • 次要终点为临床痴呆评定量表(CDR)加美国国家阿尔茨海默病协调中心(NACC)额颞叶变性(FTLD)评定量表以及神经丝轻链(NfL)水平。

主要发现

  • 非临床研究中,PR006转导患者诱导多能干细胞来源神经元并导致颗粒体蛋白前体表达,改善Grn敲除小鼠的脂褐素、溶酶体和神经炎症病理,在非人灵长类中耐受良好,仅出现轻微无症状背根神经节病。
  • 单次小脑延髓池给予PR006总体安全且耐受良好。
  • 所有患者脑脊液中出现治疗 emergent 抗AAV9抗体,但无人出现抗颗粒体蛋白前体抗体。
  • 脑脊液细胞增多是最常见的PR006相关不良事件;发生12起严重不良事件,多与PR006无关;3例患者发生深静脉血栓;1例死亡(无关)发生在治疗后18个月。
  • PR006治疗后所有患者脑脊液颗粒体蛋白前体升高;大多数患者血液颗粒体蛋白前体升高但仅为暂时性;NfL水平在PR006治疗后暂时升高,可能反映背根神经节毒性;基于CDR量表的进展率在FTD患者报告的宽泛范围内。

局限性

  • 需要更长随访和额外研究来确认PR006的安全性和潜在疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

GRN mutations cause progranulin haploinsufficiency, which eventually leads to frontotemporal dementia (FTD-GRN). PR006 is an investigational gene therapy delivering the granulin gene (GRN) using an adeno-associated virus serotype 9 (AAV9) vector. In non-clinical studies, PR006 transduced neurons derived from induced pluripotent stem cells of patients with FTD-GRN, resulted in progranulin expression and improvement of lipofuscin, lysosomal and neuroinflammation pathologies in Grn-knockout mice, and was well tolerated except for minimal, asymptomatic dorsal root ganglionopathy in non-human primates. We initiated a first-in-human phase 1/2 open-label trial. Here we report results of a pre-specified interim analysis triggered with the last treated patient of the low-dose cohort (n = 6) reaching the 12-month follow-up timepoint. We also include preliminary data from the mid-dose cohort (n = 7). Primary endpoints were safety, immunogenicity and change in progranulin levels in cerebrospinal fluid (CSF) and blood. Secondary endpoints were Clinical Dementia Rating (CDR) plus National Alzheimer's Disease Coordinating Center (NACC) Frontotemporal Lobar Degeneration (FTLD) rating scale and levels of neurofilament light chain (NfL). One-time administration of PR006 into the cisterna magna was generally safe and well tolerated. All patients developed treatment-emergent anti-AAV9 antibodies in the CSF, but none developed anti-progranulin antibodies. CSF pleocytosis was the most common PR006-related adverse event. Twelve serious adverse events occurred, mostly unrelated to PR006. Deep vein thrombosis developed in three patients. There was one death (unrelated) occurring 18 months after treatment. CSF progranulin increased after PR006 treatment in all patients; blood progranulin increased in most patients but only transiently. NfL levels transiently increased after PR006 treatment, likely reflecting dorsal root ganglia toxicity. Progression rates, based on the CDR scale, were within the broad ranges reported for patients with FTD. These data provide preliminary insights into the safety and bioactivity of PR006. Longer follow-up and additional studies are needed to confirm the safety and potential efficacy of PR006. ClinicalTrials.gov identifier: NCT04408625 .

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Sevigny J, Uspenskaya O, Heckman LD, et al. Progranulin AAV gene therapy for frontotemporal dementia: translational studies and phase 1/2 trial interim results. Nat Med. 2024. PMID: 38745011. doi:10.1038/s41591-024-02973-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。